keyword
MENU ▼
Read by QxMD icon Read
search

Fingolimod

keyword
https://www.readbyqxmd.com/read/29141823/delayed-lymphocyte-re-population-following-discontinuation-of-dimethyl-fumarate-and-after-switching-to-other-disease-modifying-drug-therapies
#1
Bhupendra O Khatri, Sergey S Tarima, Benjamin Essig, Jean Sesing, Tayo Olapo
BACKGROUND: Dimethyl fumarate (DMF) reduces absolute lymphocyte counts, CD4, and CD8 counts, without significantly affecting total white blood cell counts. However, the recovery rate of these cells after discontinuation of DMF is unknown. The effect of subsequent disease modifying therapies (DMTs) on re-population rate is also unknown. OBJECTIVES: 1. To study the re-population rate of absolute lymphocytes, CD4, and CD8 counts back to baseline after discontinuation of DMF...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29141809/treatment-satisfaction-across-injectable-infusion-and-oral-disease-modifying-therapies-for-multiple-sclerosis
#2
Tessa Eagle, Fiona Stuart, Alicia S Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L Cook, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz, Brian C Healy
BACKGROUND: The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies. METHODS: Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29141790/cerebral-toxoplasmosis-in-an-ms-patient-receiving-fingolimod
#3
Alejandro Enriquez-Marulanda, Jaime Valderrama-Chaparro, Laura Parrado, Juan Diego Vélez, Ana Maria Granados, Jorge Luis Orozco, Jairo Quiñones
Multiple Sclerosis (MS) is an autoimmune disease in which lymphocytes target putative myelin antigens in the CNS, causing inflammation and neurodegeneration. Fingolimod (FTY720) is an immunosuppressive drug used as a second line therapy for relapsing forms of MS due to its safety profile and good response to treatment. Despite its safety, there are still concerns about the possibility of Fingolimod being linked to the development of opportunistic infections like disseminated varicella zoster infections and herpes simplex encephalitis...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29140922/fingolimod-reduces-neuropathic-pain-behaviors-in-a-mouse-model-of-multiple-sclerosis-by-a-sphingosine-1-phosphate-receptor-1-dependent-inhibition-of-central-sensitization-in-the-dorsal-horn
#4
Suzanne Doolen, Tommaso Iannitti, Benjamin C Shaw, Carolyn M Grachen, Renee R Donahue, Bradley K Taylor
Multiple sclerosis (MS) is an autoimmune-inflammatory neurodegenerative disease that is often accompanied by a debilitating neuropathic pain. Disease-modifying agents slow the progression of MS and prevent relapses, yet it remains unclear if they yield analgesia. We explored the analgesic potential of fingolimod (FTY720), an agonist/functional antagonist at the sphingosine-1-phosphate receptor 1 (S1PR1), because it reduces hyperalgesia in models of peripheral inflammatory and neuropathic pain. We used a myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) mouse model of experimental autoimmune encephalomyelitis (EAE), modified to avoid frank paralysis and thus allow for assessment of withdrawal behaviors to somatosensory stimuli...
November 13, 2017: Pain
https://www.readbyqxmd.com/read/29140860/central-serous-chorioretinopathy-associated-with-fingolimod-treatment
#5
Karima S Khimani, Rod Foroozan
No abstract text is available yet for this article.
November 14, 2017: Journal of Neuro-ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society
https://www.readbyqxmd.com/read/29138683/the-evaluation-of-oxidative-stress-parameters-in-serum-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-ii-line-immunomodulatory-therapy
#6
Bożena Adamczyk, Sławomir Wawrzyniak, Sławomir Kasperczyk, Monika Adamczyk-Sowa
Objectives: The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods: One hundred and twenty-one patients with RRMS were enrolled in the study...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29138536/spotlight-on-siponimod-and-its-potential-in-the-treatment-of-secondary-progressive-multiple-sclerosis-the-evidence-to-date
#7
REVIEW
Alberto Gajofatto
Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly induced by S1P3 receptor activation, such as bradycardia and vasoconstriction...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29137549/the-impact-of-a-long-acting-oral-sphingosine-1-phosphate-analogue-on-ovarian-aging-in-a-rat-model
#8
Sezcan Mumusoglu, Volkan Turan, Hasan Uckan, Aysegul Suzer, Lale Karakoc Sokmensuer, Gurkan Bozdag
In animal studies, intravenous continuous infusion or peritoneal injection of sphingosine-1-phosphate (S1P) has been shown to decrease chemotherapy- and radiotherapy-induced apoptosis on primordial follicles. Although a long-acting oral form of an S1P analogue (FTY720, fingolimod) has been recently developed and utilized in women with multiple sclerosis, there are no data exploring its ability to avoid spontaneous follicle apoptosis. Thirty 10-month-old female rats were randomly assigned to 3 groups to investigate whether fingolimod would be able to decrease the spontaneous ovarian follicle apoptosis ratio...
January 1, 2017: Reproductive Sciences
https://www.readbyqxmd.com/read/29127856/acute-and-long-term-effects-of-fingolimod-on-heart-rhythm-and-heart-rate-variability-in-patients-with-multiple-sclerosis
#9
Ruken Özge Akbulak, Sina C Rosenkranz, Benjamin N Schaeffer, Hans O Pinnschmidt, Stephan Willems, Christoph Heesen, Boris A Hoffmann
BACKGROUND: Fingolimod can lead to increased risk of cardiac events such as bradycardia or atrioventricular (AV) block. OBJECTIVE: Evaluate acute and long-term effects of fingolimod on heart rhythm (HR), heart rate variability (HRV) and development of AV-blocks. METHODS: In 64 patients with relapsing-remitting multiple sclerosis Holter ECG monitoring (HEM) and HRV analysis were performed 24h before, six h during and 72h after initiation of fingolimod...
November 2, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29127024/the-sphingosine-1-phosphate-receptor-modulator-fingolimod-as-a-therapeutic-agent-recent-findings-and-new-perspectives
#10
REVIEW
Andrea Huwiler, Uwe Zangemeister-Wittke
The immunomodulatory drug fingolimod (FTY720, Gilenya(R)) was approved for oral treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. Pharmacologically, it acts as an unselective agonist of sphingosine 1-phosphate receptors (S1PR) and as a selective functional antagonist of the S1P1 subtype by induction of receptor downregulation. Since S1P1 is crucial for the regulation of lymphocyte trafficking, its downregulation causes redistribution of the immune cells to secondary lymphoid tissues, resulting in the depletion from the circulation and hence immunosuppression...
November 7, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29126030/evaluating-the-effect-of-adding-fish-oil-to-fingolimod-on-tnf-%C3%AE-il1%C3%AE-il6-and-ifn-%C3%AE-in-patients-with-relapsing-remitting-multiple-sclerosis-a-double-blind-randomized-placebo-controlled-trial
#11
Sasan Zandi-Esfahan, Mehdi Fazeli, Vahid Shaygannejad, Javad Hasheminia, Shervin Badihian, Maryam Aghayerashti, Helia Maghzi
OBJECTIVES: Fish oil is claimed to improve outcome in multiple sclerosis (MS) through anti-inflammatory and antioxidant effects by reducing cytokines including TNF-α, IFN-γ, IL6, and IL-1β. We aimed to evaluate the efficacy of adding fish oil to Fingolimod on these serum cytokines. PATIENTS AND METHODS: This double-blind randomized trial was conducted during April 2015 to September 2016 in Isfahan, Iran. Patients with diagnosis of relapsing remitting MS, aged 18-45years old and expanded disability status scale (EDSS) ≤5 were enrolled in the study...
October 3, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29118575/adherence-to-fingolimod-in-multiple-sclerosis-an-investigator-initiated-prospective-observational-single-center-cohort-study
#12
Andrea Zimmer, Michael Coslovsky, Ivo Abraham, Bernhard F Décard
Objectives: Adherence to multiple sclerosis (MS) treatment is essential to optimize the likelihood of full treatment effect. This prospective, observational, single-center cohort study investigated adherence to fingolimod over the 2 years following treatment initiation. Two facets of adherence - implementation and persistence - were examined and compared between new and experienced users of disease-modifying treatments (DMTs). Materials and methods: Implementation rates were based on the proportion of days covered and calculated as percentages per half-yearly visits and over 2 years, captured through refill data, pill count, and self-report...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29116601/abnormal-cervical-lymph-nodes-in-multiple-sclerosis-a-preliminary-ultrasound-study
#13
Francesca Di Giuliano, Maria Albanese, Eliseo Picchi, Francesco Mori, Fabio Buttari, Girolama Alessandra Marfia, Francesco Garaci, Nicola Biagio Mercuri, Roberto Floris, Diego Centonze, Simone Marziali
BACKGROUND: Cervical lymph nodes are the first drainage stations of the brain and therefore play a key role in neuroinflammatory disorders such as multiple sclerosis. OBJECTIVE: The aim of this study was to evaluate, by using ultrasound imaging, cervical lymph nodes in patients with multiple sclerosis and to ascertain if such patients have any clinical features to attest their role. METHODS: We enrolled 43 patients affected by relapsing-remitting multiple sclerosis (22 drug free and 21 under treatment with natalizumab or fingolimod), who underwent ultrasound examination...
November 7, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/29114096/fingolimod-protects-against-ischemic-white-matter-damage-by-modulating-microglia-toward-m2-polarization-via-stat3-pathway
#14
Chuan Qin, Wen-Hui Fan, Qian Liu, Ke Shang, Madhuvika Murugan, Long-Jun Wu, Wei Wang, Dai-Shi Tian
BACKGROUND AND PURPOSE: White matter (WM) ischemic injury, a major neuropathological feature of cerebral small vessel diseases, is an important cause of vascular cognitive impairment in later life. The pathogenesis of demyelination after WM ischemic damage are often accompanied by microglial activation. Fingolimod (FTY720) was approved for the treatment of multiple sclerosis for its immunosuppression property. In this study, we evaluated the neuroprotective potential of FTY720 in a WM ischemia model...
November 7, 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/29110882/substantial-disease-exacerbation-in-a-patient-with-relapsing-remitting-multiple-sclerosis-after-withdrawal-from-siponimod
#15
Tomasz Litwin, Łukasz Smoliński, Anna Członkowka
Among patients with multiple sclerosis, discontinuing highly effective disease-modifying treatments can potentially lead to severe disease recurrence, especially cessation of natalizumab and fingolimod. Similar to fingolimod, siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes. In the present case report, we describe a patient with MS who experienced substantial disease exacerbation after withdrawal from siponimod.
October 13, 2017: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29108879/remyelination-modulators-in-multiple-sclerosis-patients
#16
Rabeah Al-Temaimi, Jehad AbuBaker, Irina Al-Khairi, Raed Alroughani
Multiple Sclerosis (MS) is a complex autoimmune neuro-inflammatory disorder characterized by persistent MS plaques in the central nervous system. Resolution of MS plaques is dependent on the remyelination competence of surviving oligodendrocytes and surrounding environment. Here, we assessed myelination modulators in a 100 MS patients against 77 healthy controls. Plasma fractions were used for the assessment of insulin growth factor binding protein1 (IGFBP1), brain-derived neurotrophic factor (BDNF), and lipocalin2 (LCN2) using a Luminex multiplex assay, whereas neurofilament light chain (NF-L) was assessed with an enzyme-linked immunosorbent assay...
November 8, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/29108666/mycosis-fungoides-a-cutaneous-lymphoproliferative-disorder-in-a-patient-treated-with-fingolimod-for-multiple-sclerosis
#17
Zeev Nitsan, Nihal Kucuk, Shmuel Appel, Natalia Tichmanovich, Michael Osherov, Ron Milo
Fingolimod was the first oral disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis (MS). It has previously been associated with rare cases of lymphoma. Here we describe the first case of mycosis fungoides - a cutaneous lymphoproliferative disorder, in an MS patient treated with fingolimod. who developed histologically confirmed mycosis fungoides 3 years after starting fingolimod. The drug was withdrawn and the patient was treated with radiotherapy and surgical excision with remission...
November 3, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29102163/assessing-the-cerebral-gray-matter-volume-in-response-to-fingolimod-therapy-in-multiple-sclerosis-a-more-analytic-view
#18
EDITORIAL
Jeanie C McGee, Alireza Minagar
No abstract text is available yet for this article.
October 13, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29093064/assessing-association-of-comorbidities-with-treatment-choice-and-persistence-in-ms-a-real-life-multicenter-study
#19
Alice Laroni, Alessio Signori, Giorgia T Maniscalco, Roberta Lanzillo, Cinzia Valeria Russo, Eleonora Binello, Salvatore Lo Fermo, Annamaria Repice, Pietro Annovazzi, Simona Bonavita, Marinella Clerico, Damiano Baroncini, Luca Prosperini, Sara La Gioia, Silvia Rossi, Eleonora Cocco, Jessica Frau, Valentina Torri Clerici, Elisabetta Signoriello, Arianna Sartori, Ignazio Roberto Zarbo, Sarah Rasia, Cinzia Cordioli, Raffaella Cerqua, Alessia Di Sapio, Luigi Lavorgna, Simona Pontecorvo, Caterina Barrilà, Francesco Saccà, Barbara Frigeni, Sabrina Esposito, Domenico Ippolito, Fabio Gallo, Maria Pia Sormani
OBJECTIVE: To assess whether the presence of concomitant diseases at multiple sclerosis (MS) diagnosis is associated with the choice and the treatment persistence in an Italian MS cohort. METHODS: We included newly diagnosed patients (2010-2016) followed in 20 MS centers and collected demographic and clinical data. We evaluated baseline factors related to the presence of comorbidities and the association between comorbidities and the clinical course of MS and the time to the first treatment switch...
November 1, 2017: Neurology
https://www.readbyqxmd.com/read/29079163/fingolimod-induces-baff-and-expands-circulating-transitional-b-cells-without-activating-memory-b-cells-and-plasma-cells-in-multiple-sclerosis
#20
Yusei Miyazaki, Masaaki Niino, Eri Takahashi, Masako Suzuki, Masanori Mizuno, Shin Hisahara, Toshiyuki Fukazawa, Itaru Amino, Fumihito Nakano, Masakazu Nakamura, Sachiko Akimoto, Naoya Minami, Naoto Fujiki, Shizuki Doi, Shun Shimohama, Yasuo Terayama, Seiji Kikuchi
Patients with multiple sclerosis (MS) who are treated with fingolimod have an increased proportion of transitional B cells in the circulation, but the underlying mechanism is not known. We hypothesized that B cell-activating factor of the tumor necrosis factor family (BAFF) is involved in the process. Compared with healthy controls and untreated MS patients, fingolimod-treated MS patients had significantly higher serum concentrations of BAFF, which positively correlated with the proportions and the absolute numbers of transitional B cells in blood...
October 25, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
keyword
keyword
27291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"